Physician profile
Conigliaro Jones
NPI 1811967458
$13,763.53
in general payments reported to CMS, 2019-2025
64 companies · $1,090 in 2025
The $1,090 reported for 2025 was more than what 87% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,989 · 2020: $1,779 · 2021: $2,364 · 2022: $2,435 · 2023: $1,861 · 2024: $2,245 · 2025: $1,090.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,946 · Honoraria: $250.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,946.43 |
| Honoraria | $250.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,376.24 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Abbvie INC. | $2,341.79 | 2019-2025 | |
| Glaxosmithkline, LLC. | $804.33 | 2019-2024 | Trelegy Ellipta, Arexvy, Shingrix |
| Novo Nordisk INC | $646.38 | 2019-2025 | Wegovy, Ozempic, Rybelsus |
| Lilly USA, LLC | $553.22 | 2019-2025 | Mounjaro, Jardiance, Trulicity |
| Sanofi-Aventis U.S. LLC | $539.90 | 2019-2023 | |
| Arbor Pharmaceuticals, INC. | $454.79 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $446.42 | 2019-2025 | Jardiance |
| Abbott Laboratories | $388.62 | 2021-2025 | Freestyle Libre 3 |
| Bayer Healthcare Pharmaceuticals INC. | $364.31 | 2022-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $328.55 | 2019-2024 | Trintellix |
| Currax Pharmaceuticals LLC | $311.49 | 2020-2025 | Contrave, Nexletol, Nexlizet |
| Eisai INC. | $250.44 | 2020-2024 | |
| Parapro, LLC | $250.00 | 2024 | Natroba |
| Insulet Corporation | $249.91 | 2020-2023 | Omnipod |
Show all 62 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $248.06 | 2019-2024 | |
| Pfizer INC. | $211.35 | 2019-2024 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $207.94 | 2019-2024 | Xifaxan, Trulance |
| Xeris Pharmaceuticals, INC. | $186.22 | 2021-2025 | Gvoke Hypopen, Recorlev |
| Corcept Therapeutics | $177.25 | 2022-2024 | Korlym |
| Amarin Pharma, INC. | $170.66 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $166.57 | 2025 | Caplyta |
| Biohaven Pharmaceutical Holding Company LTD. | $134.50 | 2022 | |
| Amgen INC. | $122.23 | 2019-2025 | Repatha, Otezla |
| Dexcom, INC. | $113.57 | 2021-2023 | Dexcom G6 Transmitter |
| Azurity Pharmaceuticals, INC. | $96.14 | 2023 | Horizant, Edarbi |
| Supernus Pharmaceuticals, INC. | $93.03 | 2019-2020 | |
| Clarus Therapeutics INC. | $92.66 | 2021 | |
| Merck Sharp & Dohme LLC | $88.21 | 2019-2025 | Capvaxive |
| Otsuka America Pharmaceutical, INC. | $78.41 | 2022-2024 | Rexulti |
| Esperion Therapeutics, INC. | $75.99 | 2021-2024 | Nexletol |
| Idorsia Pharmaceuticals US INC | $74.01 | 2022-2023 | Quviviq |
| Janssen Pharmaceuticals, INC | $73.95 | 2019-2021 | |
| Ironwood Pharmaceuticals, INC | $71.20 | 2021-2022 | |
| Cipher Pharmaceuticals US LLC | $70.94 | 2025 | Natroba, Spinosad |
| Hikma Pharmaceuticals USA | $62.73 | 2021-2023 | Ryaltris |
| Tolmar, INC. | $61.71 | 2023-2025 | Jatenzo |
| Renalytix Ai, INC. | $57.68 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Paratek Pharmaceuticals, INC. | $56.14 | 2024-2025 | Nuzyra |
| Exact Sciences Corporation | $54.57 | 2023-2025 | Cologuard Collection Kit |
| Cequr Corporation | $51.65 | 2022-2023 | Cequr Simplicity |
| Axsome Therapeutics, INC. | $50.46 | 2024-2025 | Auvelity |
| Alnylam Pharmaceuticals INC. | $47.73 | 2022 | |
| Nestle Healthcare Nutrition INC. | $46.57 | 2021-2023 | |
| Biohaven Pharmaceuticals, INC. | $45.02 | 2021 | |
| Corium, LLC | $44.39 | 2022-2023 | Azstarys |
| E.R. Squibb & Sons, L.L.C. | $44.01 | 2019-2021 | |
| Ultragenyx Pharmaceutical INC. | $35.16 | 2022-2023 | |
| Alfasigma USA, INC. | $28.11 | 2020 | |
| Valeritas, INC. | $24.95 | 2019 | |
| Allergan, INC. | $24.75 | 2020 | |
| Vivus LLC | $17.97 | 2025 | Pancreaze |
| Verity Pharmaceuticals INC. | $17.38 | 2025 | Tlando |
| Metuchen Pharmaceuticals | $17.12 | 2019 | |
| Daiichi Sankyo INC. | $16.76 | 2024 | Injectafer |
| Shionogi INC | $15.93 | 2019 | |
| Phathom Pharmaceuticals, INC. | $15.79 | 2024 | Voquezna |
| Astellas Pharma US INC | $15.53 | 2023 | Veozah |
| Antares Pharma, INC. | $15.40 | 2024 | Xyosted |
| Inari Medical, INC. | $13.36 | 2024 | Flowtriever Catheter, S, Ct Thrombectomy System Kit |
| Alkermes, INC. | $11.84 | 2019 | |
| Shire North American Group INC | $11.54 | 2019 |
2 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Conigliaro Jones listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.